Retevmo Health Insurance Coverage Expands Access for Thyroid Cancer and Lung Cancer Patients
Progressive and metastatic RET-mutant medullary thyroid cancer patients in South Korea can now access targeted treatment within the national health insurance benefit system, according to a report. The expansion also extends first-line targeted treatment to RET fusion-positive non-small cell lung cancer, marks a move toward precision medicine.
Korean Lung Cancer Prevalence and Clinical Trial Results for Selpercatinib
Lung cancer newly affected approximately 32,000 patients in South Korea in 2023, making it the second most common cancer type overall, with RET mutations appearing in roughly 1 to 2 percent of cases. Global phase 3 clinical trial data from the LIBRETTO-431 study demonstrated a median progression-free survival of 24.8 months for treatment-naive RET fusion-positive advanced non-small cell lung cancer patients receiving selpercatinib, compared to 11.2 months for those treated with platinum-based chemotherapy paired with a PD-1 inhibitor. The LIBRETTO-001 trial showed a central nervous system objective response rate of 85 percent and a complete response rate of 27 percent in patients with measurable brain metastases who previously received platinum-based chemotherapy.
Medullary Thyroid Cancer Realities and Clinical Data from the LIBRETTO-531 Study
Hereditary medullary thyroid cancer stems from RET mutations in approximately 98 percent of cases, and patients carrying these alterations historically faced poor prognoses and limited treatment choices outside of multi-kinase inhibitors. To evaluate the efficacy of selpercatinib in this population, the global phase 3 LIBRETTO-531 trial directly compared the targeted therapy against investigator's choice of standard care with cabozantinib or vandetanib in kinase inhibitor-naive patients. The trial revealed a 12-month progression-free survival rate of 86.8 percent for the selpercatinib arm versus 65.7 percent for the control group, representing a 72 percent reduction in the risk of disease progression or death.
Timeline of Retevmo Approval and Reimbursement Implementation
- March 2022: The Ministry of Food and Drug Safety granted domestic approval to Retevmo through expedited review for RET fusion-positive non-small cell lung cancer, RET fusion-positive thyroid cancer, and RET-mutant medullary thyroid cancer.
- 27: Eli Lilly Korea held a press conference commemorating the health insurance reimbursement listing for Retevmo.
- 1: National health insurance coverage officially took effect for eligible patients with RET fusion-positive non-small cell lung cancer and advanced or metastatic RET-mutant medullary thyroid cancer requiring systemic therapy.
Frequently Asked Questions About Retevmo Coverage
What specific patient groups qualify for the newly implemented health insurance coverage?
Health insurance benefits apply to adult and pediatric patients aged 12 and older with advanced or metastatic RET-mutant medullary thyroid cancer requiring systemic therapy, alongside patients with locally advanced or metastatic stage IIIB or higher non-squamous RET fusion-positive non-small cell lung cancer receiving first-line palliative treatment or later.
How does the price or financial burden change for patients under the new reimbursement policy?
While specific out-of-pocket copayment figures were not disclosed in the source reports, the health insurance listing places the targeted therapies within the national reimbursement benefit system, directly addressing prior access barriers for rare RET-mutant medullary thyroid cancer and lung cancer patients.
What regulatory milestone preceded the recent health insurance expansion?
Retevmo secured domestic product approval from the Ministry of Food and Drug Safety in March 2022 via a rapid review process.
Related reading